Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

44.4%

4 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 1

6(66.7%)

N/A

2(22.2%)

Phase 2

1(11.1%)

9Total

Phase 1(6)

N/A(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04187404Phase 1Terminated

A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

Role: lead

NCT04669171Phase 1Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Role: lead

NCT04116658Phase 1Completed

First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma

Role: lead

NCT05350501Phase 2Terminated

EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer

Role: lead

NCT05589597Phase 1Terminated

EO4010 in Previously Treated Metastatic Colorectal Carcinoma

Role: lead

NCT03709628Phase 1Completed

A Study of a FimH Blocker, EB8018, in Crohn's Disease Patients

Role: lead

NCT03196609Not ApplicableCompleted

Characteristics of the Intestinal Microbiota in Patients With Cancer

Role: collaborator

NCT02882841Not ApplicableTerminated

MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients

Role: lead

NCT02998190Phase 1Completed

First-in-Human Single and Multiple Dose of EB8018

Role: lead

All 9 trials loaded